Allergan Cash Flow - Annual (NYSE:AGN)

Add to My Stocks
$175.19 $2.14 (1.24%) AGN stock closing price Jun 20, 2018 (Closing)

The Allergan cash flow statement helps investors understand how well the company is managing its cash flows. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Allergan profits and Allergan debt. Allergan cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Allergan had cash and cash equivalents of $1.72B at the beginning of the year and $1.82B at year end for 2017. AGN decrease in investments stood at a value of $-878M for the latest year 2017.

View details of Allergan cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Net Income Cash Flow
-4.12B14.98B3.92B-1.63B-751.1M98.3M259.1M183.3M222M238.37M
Depreciation Depletion Amortization Cash-Flow7.53B6.72B7.49B3.92B1.33B619.2M447.9M281.9M189M170.73M
Net Increase (Decrease) in Assets Liabilities933.9M-726.5M-1.27B-431.9M-163.6M-36.2M-114.4M88.9M-83.6M-37.31M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net1.53B-19.55B-5.6B383M794.79M-15.5M39.39M16.9M49.4M44.75M
Net Cash from (used by) Operating Activities
5.87B1.43B4.53B2.24B1.21B665.8M632M571M376.8M416.55M
Increase (Decrease) in Prop Plant And Equipment-342.8M-298.1M-314.8M-224.9M-170.8M-129.5M-120M-53.9M-52.4M-63.47M
Acquisition Disposition of Subsidiaires-5.29B32.61B-37.51B-5.56B-10.6M-5.51B-575.1M-67.5M-968.2M-0.65M
Increase (Decrease) in Investments5.37B-7.97B858.7M11M33.2M-103M-7.5M55.7M1M7.78M
Other Cash Inflow (Outflow) from Investment Activities-614.3M-2M-154.7M405.6M-127.1M-6.2M-16.4M-8.4M-16.5M-37.01M
Net Cash from (used by) Investment Activities
-878M24.33B-37.12B-5.37B-275.3M-5.75B-719M-74.1M-1.04B-93.35M
Issuance (Purchase) of Equity Shares-309.6M-14.9B9.11B-24.2M-122M2.69M40.7M48.4M29.8M7.55M
Issuance (Repayment) of Debt Securities-2.86B-9.8B25B1.95B-1.35B4.99B-428.8M-459.7M323.3M-95.63M
Increase (Decrease) in Bank & Other Borrowings---1.28B555M375M400M--67.9M
Payment of Dividends & Other Cash Distributions-1.22B-278.4M-208.1M-------
Other Cash from (used by) Financing Activities-532.2M-140.7M-464.8M-187.5M46.9M-173.9M4.5M---
Net Cash from (used by) Financing Activities
-4.92B-25.12B33.44B3.02B-867.3M5.19B16.4M-411.3M353.1M-20.17M
Effect of Exchange Rate Changes on Cash21.4M-8.5M-6.5M31.1M-60.9M3.3M-2.9M-4.2M--
Net Change in Cash & Cash Equivalents
93.2M628M846M-79M10M109.7M-73.5M81.4M-306.2M303.02M
Cash & Equivalents at Beginning of Year1.72B1.1B250M329M319M209.3M282.8M201.4M507.6M204.55M
Cash & Equivalents at Year End1.82B1.72B1.1B250M329M319M209.3M282.8M201.4M507.57M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Allergan stock price history and Allergan stock comparison chart inevitably reflect its cash flow situation.

  • Allergan had a Net Change in Cash and Cash Equivalents of $93.2M for the latest year 2017. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Allergan stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: Allergan reported a positive operating cash flow of $5.87B for 2017 and has seen an increase from the previous year. Operating cash flow comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Cash from investing stood at a negative value of $-878M for AGN stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $-4.92B for Allergan. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Allergan Cash Flow

FCF margin
0.39

Annual Cash Flow Statements For Allergan plc Ordinary Shares Peers

Astrazeneca cash flow, GlaxoSmithKline cash flow, Merck cash flow, Mylan cash flow, Teva Pharmaceutical cash flow